Form 13G 89bio For: 14 November
- Investing.com
Pegozafermin's Promise | Explore 89bio's lead candidate in Phase III trials for MASH and SHTG, potentially unlocking billion-dollar market opportunities in liver and cardio-metabolic diseases |
Market Dynamics | Delve into the evolving landscape of MASH treatments, including the impact of GLP-1 therapies and how pegozafermin aims to differentiate itself |
Financial Outlook | Analyst targets range from $12 to $49 per share, reflecting varied assumptions about pegozafermin's potential across multiple indications |
Strategic Positioning | Learn how 89bio's pipeline-in-a-product strategy and favorable regulatory environment could shape its future in the competitive biopharmaceutical space |
Metrics to compare | ETNB | Peers Peers - average of corresponding metrics from companies closely matching ETNB: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipETNBPeersSector |
|---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price/Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |